Adaptive Biotechnologies Raises FY 2026 MRD Revenue Forecast to $276 Million-$286 Million

Adaptive Biotechnologies reported $83.9 million in revenue for the third quarter of 2026, exceeding analyst expectations. The company achieved total company profitability during the quarter, recording an adjusted EBITDA of $14.3 million and free cash flow of $7.7 million. Core MRD revenue grew 44% excluding milestones, and the company delivered 39,587 clonoSEQ tests, a 46% increase compared to the same period in 2025. Following these results, Adaptive raised its full-year 2026 MRD revenue guidance to a range of $276 million to $286 million, up from its previous forecast of $268 million to $278 million. Additionally, the company submitted a technical assessment to MolDX seeking a new Medicare bundle for maintenance testing in multiple myeloma.